News

FDA approves new twice-yearly HIV shot. What to know
The FDA approved Gilead's HIV prevention drug lenacapavir, a twice-a-year injectable medication that clinical trials show ...
FDA approves the world's only twice-a-year shot to prevent HIV
The U.S. Food and Drug Administration has approved the world’s only twice-a-year shot to prevent HIV. (Scripps News) ...
Here's how a new FDA-approved drug can help prevent HIV
The Food and Drug Administration has approved a new injectable drug that can help prevent HIV. Dr. Amesh Adalja, a senior ...
FDA approves first twice-yearly injection that prevents HIV infection
The U.S. Food and Drug Administration (FDA) approved a new, twice-yearly shot — the first and only of its kind — to prevent ...
HIV prevention drug lenacapavir approved by FDA as twice-yearly injection
Clinical trials showed 99.9% of participants who received the drug, called Yeztugo​ from company Gilead Sciences, remained ...
FDA approves powerful HIV drug that nearly eliminated spread in clinical trials
The Food and Drug Administration has approved a highly effective new HIV-prevention medication, Gilead Sciences reported ...
FDA approves Gilead's twice-yearly HIV prevention injection, offering a powerful and convenient new option
The launch of the injection faces potential threats, including the Trump administration’s proposed cuts to federal funding ...
US FDA Approves Gilead's Twice-Yearly Injection for HIV Prevention
(Reuters) -The U.S. Food and Drug Administration on Wednesday approved Gilead Sciences' lenacapavir, a twice-yearly injection ...
The FDA Approves Powerful HIV Prevention Drug
But the Trump administration’s cuts to HIV programs in the U.S. and abroad could undermine the drug’s rollout.
FDA approves twice-a-year injection for HIV prevention
A drug currently used to treat certain HIV infections has also, on Wednesday, received approval from the US Food and Drug ...
FDA Approves a Twice-Yearly Shot to Prevent HIV
The approval could slow new infections and move the world closer to eliminating HIV. But huge obstacles remain.